Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25;16(3):e0249243.
doi: 10.1371/journal.pone.0249243. eCollection 2021.

Development and performance of CUHAS-ROBUST application for pulmonary rifampicin-resistance tuberculosis screening in Indonesia

Affiliations

Development and performance of CUHAS-ROBUST application for pulmonary rifampicin-resistance tuberculosis screening in Indonesia

Bumi Herman et al. PLoS One. .

Abstract

Background and objectives: Diagnosis of Pulmonary Rifampicin Resistant Tuberculosis (RR-TB) with the Drug-Susceptibility Test (DST) is costly and time-consuming. Furthermore, GeneXpert for rapid diagnosis is not widely available in Indonesia. This study aims to develop and evaluate the CUHAS-ROBUST model performance, an artificial-intelligence-based RR-TB screening tool.

Methods: A cross-sectional study involved suspected all type of RR-TB patients with complete sputum Lowenstein Jensen DST (reference) and 19 clinical, laboratory, and radiology parameter results, retrieved from medical records in hospitals under the Faculty of Medicine, Hasanuddin University Indonesia, from January 2015-December 2019. The Artificial Neural Network (ANN) models were built along with other classifiers. The model was tested on participants recruited from January 2020-October 2020 and deployed into CUHAS-ROBUST (index test) application. Sensitivity, specificity, and accuracy were obtained for assessment.

Results: A total of 487 participants (32 Multidrug-Resistant/MDR 57 RR-TB, 398 drug-sensitive) were recruited for model building and 157 participants (23 MDR and 21 RR) in prospective testing. The ANN full model yields the highest values of accuracy (88% (95% CI 85-91)), and sensitivity (84% (95% CI 76-89)) compare to other models that show sensitivity below 80% (Logistic Regression 32%, Decision Tree 44%, Random Forest 25%, Extreme Gradient Boost 25%). However, this ANN has lower specificity among other models (90% (95% CI 86-93)) where Logistic Regression demonstrates the highest (99% (95% CI 97-99)). This ANN model was selected for the CUHAS-ROBUST application, although still lower than the sensitivity of global GeneXpert results (87.5%).

Conclusion: The ANN-CUHAS ROBUST outperforms other AI classifiers model in detecting all type of RR-TB, and by deploying into the application, the health staff can utilize the tool for screening purposes particularly at the primary care level where the GeneXpert examination is not available.

Trial registration: NCT04208789.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart of participants recruitment.
The figure consists of two diagrams. The upper diagram illustrates the selection of data for model building and the lower diagram for the prospective data collection. Notice that some prospective participants were excluded due to procedural reasons. As 40 people were excluded for showing no growth on Lowenstein Jensen culture after eight weeks. Four in-patient participants were scheduled to have a DST but later pronounced death before DST could take place.
Fig 2
Fig 2. ANN structure of the CUHAS-ROBUST model.
This figure depicts the ANN model with 19 parameters, two hidden layers with two nodes in each layer and the blue lines show the weight of bias in each node.

References

    1. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. - PubMed
    1. WHO. Global Tuberculosis Report. Geneva: World Health Organization; 2019.
    1. Kaur R, Jindal N, Arora S, Kataria S. Epidemiology of Rifampicin Resistant Tuberculosis and Common Mutations in rpoB Gene of Mycobacterium tuberculosis: A Retrospective Study from Six Districts of Punjab (India) Using Xpert MTB/RIF Assay. J Lab Physicians. 2016;8(2):96–100. 10.4103/0974-2727.180789 - DOI - PMC - PubMed
    1. Orlando S, Triulzi I, Ciccacci F, Palla I, Palombi L, Marazzi MC, et al.. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLoS One. 2018;13(7):e0200523. 10.1371/journal.pone.0200523 - DOI - PMC - PubMed
    1. Joshi B, Lestari T, Graham SM, Baral SC, Verma SC, Ghimire G, et al.. The implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: A mixed-methods analysis. PLOS ONE. 2018;13(8):e0201731. 10.1371/journal.pone.0201731 - DOI - PMC - PubMed

Publication types

Associated data